Physician profile
Michael Cerullo
NPI 1649345026
$1,927.43
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $752 · 2020: $515 · 2021: $635 · 2022: $25.72.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $506.28 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $487.93 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $246.44 | 2019-2021 | |
| Alkermes, INC. | $175.34 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $153.96 | 2019-2021 | |
| Abbvie INC. | $71.10 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $59.83 | 2021 | |
| Lundbeck LLC | $57.36 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $50.49 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $44.96 | 2019 | |
| Shire North American Group INC | $39.68 | 2019 | |
| Allergan, INC. | $11.46 | 2019 | |
| Avanir Pharmaceuticals, INC. | $11.40 | 2020 | |
| Neurocrine Biosciences, INC. | $11.20 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Cerullo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.